Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer and Coley will seek an indication for first-line treatment of advanced non-small cell lung cancer for their toll-like receptor agonist ProMune (CPG 7909)